ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1816

Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout

Kim Coley1, Melissa Saul2 and Karen Pater1, 1Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, 2Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Economics, gout, race/ethnicity and uric acid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing worldwide, with African-Americans (AA) being affected more than Caucasians.  We evaluated the association between race, uric acid levels, urate-lowering therapy (ULT) and resource utilization in patients with gout in a large health system.

Methods: The study population was a cohort of African-American and Caucasian men and women with gout who had an inpatient or emergency department encounter at a large health system in Southwestern Pennsylvania between 10/1/2008 and 9/30/2011.  To be included, subjects had to have an ICD-9-CM code for gout (274.xx) as a either primary or secondary diagnosis during the study timeframe. A mean uric acid (UA) level was calculated for each patient across the study period and categorized as either <6 or ≥ 6 mg/dL.  ULT was identified during the hospitalization. All patient encounters where gout was listed as the primary diagnosis were collected to assess gout resource use. Chi-square and T-tests were used to compare categorical and continuous data, respectively.  Logistic regression was conducted to determine the relationship between race, UA levels, and resource utilization.

Results: There were 8,483 patients who met study criteria: 5,998 (71%) were male and 7,073 (83%) were Caucasian. UA levels were available in 43% of patients; a higher percentage of AA had UA levels assessed compared to Caucasians (53% vs. 41%, p<0.001). After stratifying by sex, mean UA levels were similar for females, however AA men had higher mean UA levels than Caucasian men (7.9 vs. 7.1, p<0.001).  Despite having higher UA levels, only 27% of AA received ULT compared to 39% of Caucasians (p<0.001). There were no differences between the sexes with respect to the use of ULT. Multivariate regression analysis revealed that patients with a UA level ≥ 6 mg/dL were more likely to be AA race (OR=1.5), male (OR=1.2), and have chronic kidney disease (OR=1.4) and less likely to be on ULT (OR=0.7). Additionally, after controlling for other variables, AA patients (OR=2.6) and those with high UA levels (OR=2.5) were more likely to have inpatient and emergency department visits for gout (p<0.001).

Conclusion: AA race is associated with higher UA levels and lower use of ULT.  AA patients and those with high UA levels were more likely to have emergency department visits or be hospitalized for gout. Improving access to ULT may reduce the burden of gout in African-Americans and reduce overall healthcare costs.


Disclosure:

K. Coley,
None;

M. Saul,
None;

K. Pater,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/relationship-between-race-uric-acid-levels-urate-lowering-therapy-and-resource-use-in-patients-with-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology